Express Pharma
Home  »  Drug approvals  »  AstraZeneca gets DCGI nod to import and market Olaparib film coated tablets

AstraZeneca gets DCGI nod to import and market Olaparib film coated tablets

It is additionally indicated as a monotherapy to treat adults with metastatic castration-resistant prostate cancer and homologous recombination repair gene mutations

1 8,517
Read Article

AstraZeneca Pharma India informed that it has received import and market permission in Form CT-20 (marketing authorisation) from the Drugs Controller General of India (DCGI) for Olaparib film-coated tablets 100 mg and 150 mg – additional indication.

Through this approval, Olaparib film-coated tablets 100 mg and 150 mg is additionally indicated as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene mutations (germline and/or somatic) who have progressed following a prior new hormonal agent.

The receipt of this import and market permission paves way for the launch of Olaparib film-coated tablets 100 mg and 150 mg (Lynparza) in India for the specified additional indication, subject to the receipt of related statutory approvals and licenses

1 Comment
  1. Atul says

    Excellent decision by DCGI need to be implement fasttrack.

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image